Lenalidomide Use as Part of Induction Chemotherapy Does Not Increase the Risk Of Peri-Transplant Venous Thromboembolic Events (VTE) in Patients Who Undergo Autologous Stem Cell Transplant for Multiple Myeloma
Lenalidomide (len) is approved for treatment in Multiple Myeloma (MM) Use of len has been associated with an increase in venous thrombotic events (VTE) and aspirin prophylaxis is recommended for pts who are on active treatment with len. Autologous stem cell transplant (ASCT) is used during the treatment of MM after initial induction therapy. The use of intravenous catheters and hospitalization increase the risk of VTE in peri-transplant period.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Naresh Bumma, Monica Peravali, Ghayathri Jeyakumar, Seongho Kim, Asif Alavi, Divaya Bhutani, Lois Ayash, Voravit Ratanatharathorn, Joseph Uberti, Abhinav Deol Tags: Multiple Myeloma Source Type: research
More News: Aspirin | Chemotherapy | Leukemia | Lymphoma | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Transplants